Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (371-380 of 706) with videos related to

Pageof 71
Sort By:
European Heart Journal|March 15, 2008
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18David A Morrow, Marc S Sabatine, Marie-Luise Brennan, et al.
Journal of the American Heart Association|October 26, 2017
Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) TrialChristina L Fanola, David A Morrow, Christopher P Cannon, et al.
The American Journal of Cardiology|September 5, 2006
Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28)C Michael Gibson, Hung Q Ly, Sabina A Murphy, et al.
Kidney International|March 13, 2018
Efficacy and safety of lipid lowering by alirocumab in chronic kidney diseasePeter P Toth, Jamie P Dwyer, Christopher P Cannon, et al.
Clinical Chemistry|August 25, 2007
Clinical application of C-reactive protein across the spectrum of acute coronary syndromesBenjamin M Scirica, David A Morrow, Christopher P Cannon, et al.
Journal of Lipid Research|November 23, 2012
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapibMichael Davidson, Sherry Xueyu Liu, Philip Barter, et al.
JAMA|October 24, 2013
Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysisJacob A Udell, Rami Zawi, Deepak L Bhatt, et al.
Circulation|December 28, 2018
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME TrialDavid Fitchett, Silvio E Inzucchi, Christopher P Cannon, et al.
JAMA|September 7, 2005
Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY studyMarc S Sabatine, Christopher P Cannon, C Michael Gibson, et al.
JAMA|June 16, 2005
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trialsShamir R Mehta, Christopher P Cannon, Keith A A Fox, et al.
Pageof 71

Showing results (371-380 of 706) with videos related to

Sort By:
Pageof 71
European Heart Journal|March 15, 2008
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18David A Morrow, Marc S Sabatine, Marie-Luise Brennan, et al.
Journal of the American Heart Association|October 26, 2017
Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) TrialChristina L Fanola, David A Morrow, Christopher P Cannon, et al.
The American Journal of Cardiology|September 5, 2006
Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28)C Michael Gibson, Hung Q Ly, Sabina A Murphy, et al.
Kidney International|March 13, 2018
Efficacy and safety of lipid lowering by alirocumab in chronic kidney diseasePeter P Toth, Jamie P Dwyer, Christopher P Cannon, et al.
Clinical Chemistry|August 25, 2007
Clinical application of C-reactive protein across the spectrum of acute coronary syndromesBenjamin M Scirica, David A Morrow, Christopher P Cannon, et al.
Journal of Lipid Research|November 23, 2012
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapibMichael Davidson, Sherry Xueyu Liu, Philip Barter, et al.
JAMA|October 24, 2013
Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysisJacob A Udell, Rami Zawi, Deepak L Bhatt, et al.
Circulation|December 28, 2018
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME TrialDavid Fitchett, Silvio E Inzucchi, Christopher P Cannon, et al.
JAMA|September 7, 2005
Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY studyMarc S Sabatine, Christopher P Cannon, C Michael Gibson, et al.
JAMA|June 16, 2005
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trialsShamir R Mehta, Christopher P Cannon, Keith A A Fox, et al.
Pageof 71